The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Exelixis Inc

Nasdaq: EXEL
Last

(U.S.) $5.73

Today's change+0.19 +3.43%
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.
 

Exelixis Inc

Nasdaq: EXEL
Last

(U.S.) $5.73

Today's change+0.19 +3.43%
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.

Exelixis Inc up sharply

Exelixis Inc closed up sharply Friday, rallying (U.S.)$0.19 or 3.43% to (U.S.)$5.73. Over the last five days, shares have gained 2.50% and 297.92% year to date. Shares have outperformed the S&P 500 by 33.21% during the last year.

Key company metrics

  • Open(U.S.) $5.52
  • Previous close(U.S.) $5.54
  • High(U.S.) $6.12
  • Low(U.S.) $5.51
  • Bid / Ask-- / --
  • YTD % change+297.92%
  • Volume7,412,202
  • Average volume (10-day)18,213,591
  • Average volume (1-month)9,619,402
  • Average volume (3-month)5,620,476
  • 52-week range(U.S.) $1.26 to (U.S.) $6.38
  • Beta2.86
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.17
Updated July 31 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.60%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue9767
Total other revenue--------
Total revenue9767
Gross profit9766
Total cost of revenue1110
Total operating expense32545868
Selling / general / administrative10101016
Research & development22404451
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0340
Other operating expenses, total--------
Operating income-23-46-52-62
Interest income (expense), net non-operating-12-12-12-12
Gain (loss) on sale of assets--------
Other--------
Income before tax-35-58-63-73
Income after tax-35-58-63-73
Income tax, total--0--0
Net income-35-58-63-73
Total adjustments to net income--------
Net income before extra. items-35-58-63-73
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-35-58-63-73
Inc. avail. to common incl. extra. items-35-58-63-73
Diluted net income-35-58-63-73
Dilution adjustment--------
Diluted weighted average shares196196195195
Diluted EPS excluding extraordinary itemsvalue per share-0.18-0.30-0.32-0.38
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.18-0.28-0.30-0.37